AC
EWTX icon

AXQ Capital’s Edgewise Therapeutics EWTX Stock Holding History

AXQ Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Sell
5,537
-3,976
-42% -$137K 0.02% 689
2026
Q1 		$300K Buy
+9,513
New +$274K 0.04% 602

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AXQ Capital's EWTX Position: Q2 2026 in Review

AXQ Capital reduced its Edgewise Therapeutics (EWTX) stake by 42% in Q2 2026, selling an estimated $137K and leaving 5,537 shares worth $225K. The position accounts for 0.02% of the portfolio, ranked #689.

AXQ Capital first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $300K in Q1 2026. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • AXQ Capital held 5,537 shares of Edgewise Therapeutics worth $225K as of Q2 2026.
  • AXQ Capital sold 3,976 Edgewise Therapeutics shares in Q2 2026, an estimated $137K.
  • Edgewise Therapeutics made up 0.02% of AXQ Capital's portfolio in Q2 2026, its #689 holding.
  • AXQ Capital first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • AXQ Capital's Edgewise Therapeutics position peaked at $300K in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.